NLS Pharmaceutics Ltd.
The Circle 6
8058 Zurich, Switzerland
January 4, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ada D. Sarmento
| Re: | NLS Pharmaceutics Ltd. | |
| Registration Statement on Form F-1 | ||
| Filed December 20, 2021 | ||
| File No. 333-261766 |
Dear Ada D. Sarmento:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, NLS Pharmaceutics Ltd. hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:00 p.m. EST on Thursday, January 6, 2022, or as soon as thereafter practicable.
| Very truly yours, | |
| /s/ Alexander Zwyer | |
| Alexander Zwyer | |
| Chief Executive Officer |
| cc: | Sullivan & Worcester LLP |
